Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 167nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 178nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 193nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 224nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
TargetMuscarinic acetylcholine receptor M1(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataKi: 341nMAssay Description:Inhibition of muscarinic acetylcholine receptor M1 (unknown origin)More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 613nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 770nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
TargetMuscarinic acetylcholine receptor M4(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataKi: 865nMAssay Description:Inhibition of muscarinic acetylcholine receptor M4 (unknown origin)More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 913nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 1.35E+3nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 2.24E+3nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 2.31E+3nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 2.36E+3nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataKi: 2.94E+3nMAssay Description:Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptorMore data for this Ligand-Target Pair
TargetMuscarinic acetylcholine receptor M2(Homo sapiens (Human))
Bristol-Myers Squibb
Curated by ChEMBL
Bristol-Myers Squibb
Curated by ChEMBL
Affinity DataKi: 4.01E+3nMAssay Description:Inhibition of muscarinic acetylcholine receptor M2 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 0.240nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: <0.450nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: <0.450nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 1nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:Inhibition of [125I]MCP1-beta binding to CCR5 in human HT1080 cell membranes incubated for 4 to 6 hrsMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
TargetC-C chemokine receptor type 3(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Bristol-Myers Squibb Pharmaceutical Research Institute
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibitory concentration against C-C chemokine receptor type 3 using human [125I]-eotaxin.More data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMAssay Description:Antagonist activity against CCR2 in human PBMC assessed as inhibition of MCP1-induced chemotaxis at 37 degCMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMT: 2°CAssay Description:Inhibition of [125I]hMCP1 binding to CCR2 in human PBMC incubated for 30 mins at room temperatureMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of [125I]MCP1-beta binding to CCR5 in human HT1080 cell membranes incubated for 4 to 6 hrsMore data for this Ligand-Target Pair